OTCMKTS:HKMPF Hikma Pharmaceuticals (HKMPF) Stock Price, News & Analysis $28.14 0.00 (0.00%) As of 02/21/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$28.14▼$28.1450-Day Range$24.06▼$28.1452-Week Range$22.33▼$28.14VolumeN/AAverage Volume38 shsMarket Capitalization$6.24 billionP/E RatioN/ADividend Yield2.27%Price TargetN/AConsensus RatingStrong Buy Company OverviewHikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More… Receive HKMPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HKMPF Stock News HeadlinesHikma Pharmaceuticals to Announce 2024 Financial ResultsFebruary 10, 2025 | tipranks.comHikma Pharmaceuticals to release annual results on February 26February 10, 2025 | investing.comBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.February 22, 2025 | Brownstone Research (Ad)Hikma Pharmaceuticals Discloses PDMR Share DisposalDecember 23, 2024 | tipranks.comHikma Pharmaceuticals: Strategic Growth and Attractive Valuation Reinforce Buy RatingNovember 8, 2024 | markets.businessinsider.comHikma Pharmaceuticals remains steady Tuesday, underperforms marketOctober 1, 2024 | marketwatch.comHikma Pharmaceuticals falls Friday, underperforms marketAugust 30, 2024 | marketwatch.comJazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High PricesAugust 28, 2024 | msn.comSee More Headlines HKMPF Stock Analysis - Frequently Asked Questions How have HKMPF shares performed this year? Hikma Pharmaceuticals' stock was trading at $24.12 at the start of the year. Since then, HKMPF stock has increased by 16.7% and is now trading at $28.1428. View the best growth stocks for 2025 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today2/22/2025Next Earnings (Estimated)2/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Private households Sub-IndustryN/A Current SymbolOTCMKTS:HKMPF Previous SymbolOTC:HKMPF CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760Fax44-20-7399-2761Employees9,100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.46 Current Ratio1.66 Quick Ratio0.98 Sales & Book Value Annual Sales$2.88 billion Price / Sales2.17 Cash Flow$3.33 per share Price / Cash Flow8.46 Book Value$10.03 per share Price / Book2.81Miscellaneous Outstanding Shares221,890,000Free FloatN/AMarket Cap$6.24 billion OptionableNot Optionable Beta0.60 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (OTCMKTS:HKMPF) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.